NCT07267806

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy as First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC): A Randomized, Controlled, Open-Label, Multicenter Phase III.

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 326 (estimated)
• Sponsor: Linhui Peng · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).

Conditions

• Hepato Cellular Carcinoma (HCC)
• Chemotherapy Effect

Interventions

Type	Name	Description
DRUG	Infusional mFOLFOX7 plus Camrelizumab and apatinib	Oxaliplatin 85mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on Dand then 2400mg/m2 for 46h of each 21 day cycle. this chemotherapy regimen should be administered for a maximum of 6 cycles. Camrelizumab 200mg infusion on D1 forevery 21 days Apatinib 250mg, po, qd for every 21 days.
DRUG	Camrelizumab and apatinib	Camrelizumab 200mg infusion on D1 forevery 21 days Apatinib 250mg, po, qd for every 21 days.

Timeline

• Start date: 2025-10-31
• Primary completion: 2029-10-01
• Completion: 2032-10-01
• First posted: 2025-12-05
• Last updated: 2025-12-16

Locations

1 site across 1 country: China